ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 141 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 2.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $633,000 | +60.3% | 33,575 | 0.0% | 0.36% | +58.4% |
| Q2 2019 | $395,000 | -13.8% | 33,575 | 0.0% | 0.23% | -16.9% |
| Q1 2019 | $458,000 | +33.1% | 33,575 | 0.0% | 0.27% | +17.2% |
| Q4 2018 | $344,000 | -38.5% | 33,575 | 0.0% | 0.23% | -29.5% |
| Q3 2018 | $559,000 | +5.5% | 33,575 | 0.0% | 0.33% | -3.5% |
| Q2 2018 | $530,000 | +24.4% | 33,575 | 0.0% | 0.34% | +23.1% |
| Q1 2018 | $426,000 | +10.9% | 33,575 | 0.0% | 0.28% | +13.1% |
| Q4 2017 | $384,000 | -6.6% | 33,575 | 0.0% | 0.24% | -13.7% |
| Q3 2017 | $411,000 | +7.0% | 33,575 | 0.0% | 0.28% | +2.9% |
| Q2 2017 | $384,000 | -45.0% | 33,575 | 0.0% | 0.28% | -46.7% |
| Q1 2017 | $698,000 | 0.0% | 33,575 | 0.0% | 0.52% | -4.4% |
| Q4 2016 | $698,000 | -36.5% | 33,575 | 0.0% | 0.54% | -38.3% |
| Q3 2016 | $1,100,000 | +31.3% | 33,575 | 0.0% | 0.88% | +30.3% |
| Q2 2016 | $838,000 | +1.9% | 33,575 | 0.0% | 0.67% | -2.9% |
| Q1 2016 | $822,000 | -25.9% | 33,575 | 0.0% | 0.69% | -25.7% |
| Q4 2015 | $1,109,000 | +0.9% | 33,575 | 0.0% | 0.93% | -4.1% |
| Q3 2015 | $1,099,000 | – | 33,575 | – | 0.97% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 229,895 | $7,593,000 | 6.73% |
| Foresite Capital Management II, LLC | 419,997 | $13,873,000 | 4.65% |
| Cormorant Asset Management, LP | 757,475 | $25,019,000 | 2.99% |
| NEXTHERA CAPITAL LP | 60,000 | $1,982,000 | 2.81% |
| SENZAR ASSET MANAGEMENT, LLC | 557,170 | $18,403,325,000 | 2.05% |
| Parametrica Management Ltd | 9,360 | $309,000 | 2.04% |
| Partner Investment Management, L.P. | 36,756 | $1,214,000 | 1.99% |
| PFM Health Sciences, LP | 1,890,030 | $62,428,000 | 1.90% |
| PYRRHO CAPITAL MANAGEMENT, LP | 63,000 | $2,081,000 | 1.40% |
| BB BIOTECH AG | 1,510,150 | $49,880,000 | 1.40% |